 | Advertisements: |
Hot themes this week:
|
| » Read discussion on King Pharmaceuticals
03/02/11 Pfizer Inc. briefly hit a one-year high Tuesday on the New York Stock Exchange , one day after completing a $3.6 billion merger with King Pharmaceuticals Inc. and announcing that a breakthrough drug had received regulatory approval in Europe.
02/08/11 BRISTOL, TN--(Marketwire - 02/08/11) - King Pharmaceuticals, Inc. (NYSE: KG - News ) (the "Company") announced today that it has submitted written notice to the New York Stock Exchange (the "NYSE") of its intention to voluntarily delist its common stock, no par value, from the NYSE. The Company intends to file a Form 25 with the Securities and Exchange Commission (the "SEC") on February 18, 2011 ...
02/08/11 BRISTOL, TN--(Marketwire - February 8, 2011) - King Pharmaceuticals, Inc. ( NYSE : KG ) (the "Company") announced today that it has submitted written notice to the New York Stock Exchange (the "NYSE") of its intention to voluntarily delist its common stock, no par value, from the NYSE. The Company intends to file a Form 25 with the Securities and Exchange Commission (the "SEC") on February 18 ...
01/31/11 BRISTOL, TN--(Marketwire - 01/31/11) - King Pharmaceuticals, Inc. (NYSE: KG - News ) (the "Company") announced today that it has commenced a tender offer (the "Convertible Notes Tender Offer") to repurchase, at the option of each holder, any and all of its outstanding 1 1/4% Convertible Senior Notes Due 2026 (the "Convertible Notes"). The Company is offering to repurchase any and all of the $400 ...
01/31/11 BRISTOL, TN--(Marketwire - January 31, 2011) - King Pharmaceuticals, Inc. ( NYSE : KG ) (the "Company") announced today that it has commenced a tender offer (the "Convertible Notes Tender Offer") to repurchase, at the option of each holder, any and all of its outstanding 1 1/4% Convertible Senior Notes Due 2026 (the "Convertible Notes"). The Company is offering to repurchase any and all of the ...
01/21/11 Pfizer Inc. (NYSE: PFE) today announced that its wholly-owned subsidiary, Parker Tennessee Corp. (Parker), has extended the expiration date of its tender offer for all outstanding shares of common stock of King Pharmaceuticals, Inc. (NYSE: KG) for $14.25 per share, net to the seller in cash, without interest thereon and subject to any required withholding taxes.
12/27/10 King Pharmaceuticals?®, Inc. and Pain Therapeutics?®, Inc. today announced that King has resubmitted a New Drug Application for REMOXY?® to the U.S. Food and Drug Administration in response to a Complete Response letter received by Pain Therapeutics in December 2008. ? This is a Class 2 resubmission with a six month review cycle.
12/27/10 BRISTOL, Tenn. and SAN MATEO, Calif. -- King Pharmaceuticals, Inc. and Pain Therapeutics, Inc. today announced that King has resubmitted a New Drug Application for REMOXY to the U.S.
12/20/10 REHOVOT, ISRAEL and PHILADELPHIA, PA--(Marketwire - 12/20/10) - Rosetta Genomics, Ltd. ("Rosetta") (NASDAQ: ROSG - News ), a leading developer and provider of microRNA-based molecular diagnostics, today announced that Brian A. Markison, Chairman and CEO of King Pharmaceuticals (NYSE: KG - News ), has become an observer to the Company's Board of Directors and, upon shareholder approval, will ...
12/20/10 CEO of King Pharmaceuticals Brings Valuable Commercial Expertise
12/15/10 NEW YORK, Dec. 15, 2010 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE) today announced that its wholly-owned subsidiary, Parker Tennessee Corp., has extended the expiration date of its tender offer for all outstanding shares of common stock of King Pharmaceuticals, Inc. (NYSE: KG) for $14.25 per share, net to the seller in cash, without interest thereon and subject to any required withholding ...
10/22/10 Pfizer's acquisition of King Pharmaceuticals promises to cut costs and position the company to be a major player in the global market for pain-relief and pain-management products and at the same time opens the door for pharmaceutical consulting specialists to help the burgeoning company remain manageable, compliant, and competitive.
10/14/10 Pfizer Inc.(NYSE: PFE) and King Pharmaceuticals, Inc. (NYSE: KG) today announced that they have entered into a definitive merger agreement. Under the terms of the agreement, Pfizer will acquire King, a diversified specialty pharmaceutical discovery and clinical development company, for $3.6 billion in cash, or $14.25 per share, which represents a premium of approximately 40% to King's closing ...
10/12/10 Pfizer Inc. and King Pharmaceuticals, Inc. today announced that they have entered into a definitive merger agreement. ? Under the terms of the agreement, Pfizer will acquire King, a diversified specialty pharmaceutical discovery and clinical development company, for $3.6 billion in cash, or $14.25 per share, which represents a premium of approximately 40% to King's closing price as of October 11 ...
10/12/10 Pfizer Inc, the world's largest pharmaceutical company by revenue, said on Tuesday it will buy pain drug maker King Pharmaceuticals Inc for $US3.6 billion ($3.67 billion) in cash.
10/12/10 Pfizer Inc. agreed to pay $3.6 billion in cash to buy King Pharmaceuticals Inc., expanding its range of pain treatments to include tamper-resistant medicines.
08/30/10 BRISTOL, TN--(Marketwire - August 30, 2010) - King Pharmaceuticals, Inc. ( NYSE : KG ) announced today the appointment of Jeffrey A. Bailey to the position of Chief Commercial Officer. Mr. Bailey will be responsible for the Company's commercial activities in the branded pharmaceutical business and will lead all Sales, Marketing, Managed Care, Sales Operations and Business Analytics. Importantly ...
08/09/10 BRISTOL, TN--(Marketwire - 08/09/10) - King Pharmaceuticals, Inc. (NYSE: KG - News ) -- REMOXY ON TRACK FOR FOURTH QUARTER 2010 RESUBMISSION -- EMBEDA PRESCRIPTIONS CONTINUE TO GROW -- FLECTOR PATCH PRESCRIPTIONS REBOUND IN JUNE, HIGHEST MONTHLY TOTAL SINCE DECEMBER -- CASH FLOW FROM OPERATIONS $51 MILLION, FULL YEAR CASH FLOW FORECAST OF $300 MILLION King Pharmaceuticals, Inc. (NYSE: KG - News ...
08/09/10 BRISTOL, TN--(Marketwire - August 9, 2010) - King Pharmaceuticals, Inc. ( NYSE : KG )
08/02/10 BRISTOL, TN--(Marketwire - August 2, 2010) - King Pharmaceuticals, Inc. ( NYSE : KG ) reported today that the Company plans to announce financial results for the second quarter ended June 30, 2010 prior to the market open on Monday, August 9, 2010. The Company also plans to provide a live conference call which may include discussion of the Company's marketed products, pipeline, financial results ...
06/29/10 BRISTOL, TN--(Marketwire - 06/29/10) - King Pharmaceuticals, Inc. (NYSE: KG - News ) $5 MILLION CASH PAYMENT REDUCES ROYALTY RATE TO 10% REMOXY NDA RESUBMISSION ON TRACK FOR Q4 2010 King Pharmaceuticals, Inc. (NYSE: KG - News ) announced today a modification to its strategic alliance with Pain Therapeutics, Inc. (NASDAQ: PTIE - News ) for REMOXY. The move signals a desire to target Europe's ... |
